glioblastoma cbd thc

Glioblastoma cbd thc

“Having recently shown that a specific cannabinoid combination given by oral spray could be safely added to temozolomide chemotherapy, we’re really excited to build on these findings to assess whether this drug could help glioblastoma patients live longer in a major randomised trial.”

Pictured: Stephen Lee with his wife

Tackling aggressive brain cancer

The new three-year phase II trial (ARISTOCRAT), funded by The Brain Tumour Charity and co-ordinated by the Cancer Research UK Clinical Trials Unit at the University of Birmingham, is due to begin recruiting more than 230 patients across all UK nations in early 2022, subject to sufficient funds being raised.

‘Life beyond a glioblastoma diagnosis’

Sativex, manufactured by GW Pharma, is an oromucosal spray containing 1:1 THC (Delta-9-tetrahydrocannabinol) and CBD (cannabidiol), with the active ingredients being absorbed in the lining of the mouth, either under the tongue or inside the cheek.

In the first part of the study, 6 patients received a personalised regime of Sativex of up to 12 sprays per day, alongside their temozolomide therapy – and the side-effects were recorded and reviewed.

“These are really promising findings and we now urgently need to see a larger clinical trial to understand whether adding cannabinoids to chemotherapy could offer precious extra time to live for people living with a glioblastoma.

While the study observed better one-year survival in the group receiving Sativex, the researchers caution that a larger, randomised trial is needed to assess whether adding Sativex to temozolomide could offer additional life-extension. The study also showed that Sativex did not appear to interfere with temozolomide treatment.

“In the meantime, and beyond, anyone affected by a glioblastoma can speak to us on 0808 800 0004 or by emailing [email protected] If you need someone to talk to or advice on where to get help, we’re here for you.”